Search

Ion Beam Applications

Затворен

10.54 -1.5

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.2

Максимум

10.8

Ключови измерители

By Trading Economics

Приходи

-10M

Продажби

206M

P/E

Средно за сектора

41.111

63.778

Дивидентна доходност

1.56

Марж на печалбата

-4.99

Служители

1,943

EBITDA

-372K

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.56%

2.39%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

342M

Предишно отваряне

12.04

Предишно затваряне

10.54

Ion Beam Applications Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.09.2024 г., 06:28 ч. UTC

Придобивния, сливания и поглъщания

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.